Increased Risk in Second Malignancy in HCL Patients by Sex, Cancer Subtype, Time After Diagnosis and Treatment Type
| . | Observed . | Expected . | Ratio . | 90% CI . | P Value . |
|---|---|---|---|---|---|
| All cancers | |||||
| Male | 22 | 7.57 | 2.91 | 1.97-4.15 | <.001 |
| Female | 4 | 2.42 | 1.65 | 0.56-3.78 | .226 |
| Both | 26 | 9.99 | 2.60 | 1.82-3.61 | <.001 |
| Exclude all squamous/basal cell ca of skin and ca in situ | |||||
| Male | 17 | 5.61 | 3.03 | 1.93-4.54 | <.001 |
| Female | 4 | 1.74 | 2.30 | 0.78-5.25 | .099 |
| Both | 21 | 7.35 | 2.86 | 1.91-4.11 | <.001 |
| Cancer subtypes* | |||||
| Colon | 3 | 0.51 | 5.83 | 1.57-15.04 | .016 |
| Lung | 2 | 1.28 | 1.28 | 0.27-4.92 | .365 |
| Prostate | 6 | 1.52 | 3.95 | 1.72-7.78 | <.001 |
| Kidney | 1 | 0.19 | 5.33 | 0.21-25.20 | .171 |
| Year after HCL diagnosis | |||||
| 0 to 1 | 3 | 1.07 | 2.80 | 0.76-7.22 | .094 |
| 1 to 2 | 8 | 1.94 | 4.13 | 2.05-7.45 | .001 |
| 3 to 5 | 5 | 2.20 | 2.27 | 0.89-4.77 | .073 |
| >6 | 7 | 3.85 | 1.82 | 0.85-3.42 | .095 |
| Type of treatment† | |||||
| IFN | 5 | 1.25 | 4.00 | 1.57-8.40 | .010 |
| IFN and PA | 13 | 4.80 | 2.71 | 1.60-4.31 | .001 |
| PA | 3 | 1.36 | 2.21 | 0.60-5.69 | .160 |
| Splenectomy | 2 | 1.65 | 1.21 | 0.21-3.81 | .340 |
| . | Observed . | Expected . | Ratio . | 90% CI . | P Value . |
|---|---|---|---|---|---|
| All cancers | |||||
| Male | 22 | 7.57 | 2.91 | 1.97-4.15 | <.001 |
| Female | 4 | 2.42 | 1.65 | 0.56-3.78 | .226 |
| Both | 26 | 9.99 | 2.60 | 1.82-3.61 | <.001 |
| Exclude all squamous/basal cell ca of skin and ca in situ | |||||
| Male | 17 | 5.61 | 3.03 | 1.93-4.54 | <.001 |
| Female | 4 | 1.74 | 2.30 | 0.78-5.25 | .099 |
| Both | 21 | 7.35 | 2.86 | 1.91-4.11 | <.001 |
| Cancer subtypes* | |||||
| Colon | 3 | 0.51 | 5.83 | 1.57-15.04 | .016 |
| Lung | 2 | 1.28 | 1.28 | 0.27-4.92 | .365 |
| Prostate | 6 | 1.52 | 3.95 | 1.72-7.78 | <.001 |
| Kidney | 1 | 0.19 | 5.33 | 0.21-25.20 | .171 |
| Year after HCL diagnosis | |||||
| 0 to 1 | 3 | 1.07 | 2.80 | 0.76-7.22 | .094 |
| 1 to 2 | 8 | 1.94 | 4.13 | 2.05-7.45 | .001 |
| 3 to 5 | 5 | 2.20 | 2.27 | 0.89-4.77 | .073 |
| >6 | 7 | 3.85 | 1.82 | 0.85-3.42 | .095 |
| Type of treatment† | |||||
| IFN | 5 | 1.25 | 4.00 | 1.57-8.40 | .010 |
| IFN and PA | 13 | 4.80 | 2.71 | 1.60-4.31 | .001 |
| PA | 3 | 1.36 | 2.21 | 0.60-5.69 | .160 |
| Splenectomy | 2 | 1.65 | 1.21 | 0.21-3.81 | .340 |
Abbreviations: CI, confidence interval; ca, carcinoma; IFN, interferon; PA, purine analogue.
Event censored at time of development of first secondary cancer for both the study and control populations. Record of events for both populations drawn from the same database.
Patients with other types or combinations of treatment excluded from analysis.